FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2768813939> ?p ?o ?g. }

• W2768813939 endingPage "801" @default.
• W2768813939 startingPage "794" @default.
• W2768813939 abstract "Purpose This work investigates a new approach to enhance radiotherapy through a photo therapeutic agent activated by Cherenkov light produced from the megavoltage photon beam. The process is termed Radiotherapy Enhanced with Cherenkov photo-Activation (RECA). RECA is compatible with various photo-therapeutics, but here we focus on use with psoralen, an ultraviolet activated therapeutic with extensive history of application in superficial and extracorporeal settings. RECA has potential to extend the scope of psoralen treatments beyond superficial to deep seated lesions. Methods and Materials In vitro studies in B16 melanoma and 4T1 murine breast cancer cells were performed to investigate the potential of RT plus RECA versus RT alone for increasing cytotoxicity (local control) and increasing surface expression of major histocompatibility complex I (MHC I). The latter represents potential for immune response amplification (increased antigen presentation), which has been observed in other psoralen therapies. Cytotoxicity assays included luminescence and clonogenics. The MHC I assays were performed using flow cytometry. In addition, Cherenkov light intensity measurements were performed to investigate the possibility of increasing the Cherenkov light intensity per unit dose from clinical megavoltage beams, to maximize psoralen activation. Results Luminescence assays showed that RECA treatment (2 Gy at 6 MV) increased cytotoxicity by up to 20% and 9.5% for 4T1 and B16 cells, respectively, compared with radiation and psoralen alone (ie, Cherenkov light was blocked). Similarly, flow cytometry revealed median MHC I expression was significantly higher in RECA-treated cells, compared with those receiving radiation and psoralen alone (approximately 450% and 250% at 3 Gy and 6 Gy, respectively, P << .0001). Clonogenic assays of B16 cells at doses of 6 Gy and 12 Gy showed decreases in tumor cell viability of 7% (P = .017) and 36% (P = .006), respectively, when Cherenkov was present. Conclusion This work demonstrates for the first time the potential for photo-activation of psoralen directly in situ, from Cherenkov light generated by a clinical megavoltage treatment beam. This work investigates a new approach to enhance radiotherapy through a photo therapeutic agent activated by Cherenkov light produced from the megavoltage photon beam. The process is termed Radiotherapy Enhanced with Cherenkov photo-Activation (RECA). RECA is compatible with various photo-therapeutics, but here we focus on use with psoralen, an ultraviolet activated therapeutic with extensive history of application in superficial and extracorporeal settings. RECA has potential to extend the scope of psoralen treatments beyond superficial to deep seated lesions. In vitro studies in B16 melanoma and 4T1 murine breast cancer cells were performed to investigate the potential of RT plus RECA versus RT alone for increasing cytotoxicity (local control) and increasing surface expression of major histocompatibility complex I (MHC I). The latter represents potential for immune response amplification (increased antigen presentation), which has been observed in other psoralen therapies. Cytotoxicity assays included luminescence and clonogenics. The MHC I assays were performed using flow cytometry. In addition, Cherenkov light intensity measurements were performed to investigate the possibility of increasing the Cherenkov light intensity per unit dose from clinical megavoltage beams, to maximize psoralen activation. Luminescence assays showed that RECA treatment (2 Gy at 6 MV) increased cytotoxicity by up to 20% and 9.5% for 4T1 and B16 cells, respectively, compared with radiation and psoralen alone (ie, Cherenkov light was blocked). Similarly, flow cytometry revealed median MHC I expression was significantly higher in RECA-treated cells, compared with those receiving radiation and psoralen alone (approximately 450% and 250% at 3 Gy and 6 Gy, respectively, P << .0001). Clonogenic assays of B16 cells at doses of 6 Gy and 12 Gy showed decreases in tumor cell viability of 7% (P = .017) and 36% (P = .006), respectively, when Cherenkov was present. This work demonstrates for the first time the potential for photo-activation of psoralen directly in situ, from Cherenkov light generated by a clinical megavoltage treatment beam." @default.
• W2768813939 created "2017-12-04" @default.
• W2768813939 creator A5001099948 @default.
• W2768813939 creator A5008287681 @default.
• W2768813939 creator A5024977301 @default.
• W2768813939 creator A5027211051 @default.
• W2768813939 creator A5041293360 @default.
• W2768813939 creator A5071168060 @default.
• W2768813939 creator A5071519548 @default.
• W2768813939 creator A5079311965 @default.
• W2768813939 creator A5086491608 @default.
• W2768813939 date "2018-03-01" @default.
• W2768813939 modified "2023-10-15" @default.
• W2768813939 title "Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy" @default.
• W2768813939 cites W130210233 @default.
• W2768813939 cites W1950026217 @default.
• W2768813939 cites W1974996696 @default.
• W2768813939 cites W1982734458 @default.
• W2768813939 cites W1989994128 @default.
• W2768813939 cites W2024594863 @default.
• W2768813939 cites W2027391743 @default.
• W2768813939 cites W2028650845 @default.
• W2768813939 cites W2029550173 @default.
• W2768813939 cites W2032417358 @default.
• W2768813939 cites W2036839577 @default.
• W2768813939 cites W2038836187 @default.
• W2768813939 cites W2089039025 @default.
• W2768813939 cites W2090191181 @default.
• W2768813939 cites W2091179436 @default.
• W2768813939 cites W2100166947 @default.
• W2768813939 cites W2106618401 @default.
• W2768813939 cites W2217162962 @default.
• W2768813939 cites W2345613754 @default.
• W2768813939 cites W2472226382 @default.
• W2768813939 cites W2799881016 @default.
• W2768813939 cites W4254126892 @default.
• W2768813939 cites W64452830 @default.
• W2768813939 doi "https://doi.org/10.1016/j.ijrobp.2017.11.013" @default.
• W2768813939 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6819994" @default.
• W2768813939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29413289" @default.
• W2768813939 hasPublicationYear "2018" @default.
• W2768813939 type Work @default.
• W2768813939 sameAs 2768813939 @default.
• W2768813939 citedByCount "17" @default.
• W2768813939 countsByYear W27688139392018 @default.
• W2768813939 countsByYear W27688139392019 @default.
• W2768813939 countsByYear W27688139392020 @default.
• W2768813939 countsByYear W27688139392021 @default.
• W2768813939 countsByYear W27688139392022 @default.
• W2768813939 countsByYear W27688139392023 @default.
• W2768813939 crossrefType "journal-article" @default.
• W2768813939 hasAuthorship W2768813939A5001099948 @default.
• W2768813939 hasAuthorship W2768813939A5008287681 @default.
• W2768813939 hasAuthorship W2768813939A5024977301 @default.
• W2768813939 hasAuthorship W2768813939A5027211051 @default.
• W2768813939 hasAuthorship W2768813939A5041293360 @default.
• W2768813939 hasAuthorship W2768813939A5071168060 @default.
• W2768813939 hasAuthorship W2768813939A5071519548 @default.
• W2768813939 hasAuthorship W2768813939A5079311965 @default.
• W2768813939 hasAuthorship W2768813939A5086491608 @default.
• W2768813939 hasBestOaLocation W27688139392 @default.
• W2768813939 hasConcept C109316439 @default.
• W2768813939 hasConcept C120665830 @default.
• W2768813939 hasConcept C121332964 @default.
• W2768813939 hasConcept C202751555 @default.
• W2768813939 hasConcept C203014093 @default.
• W2768813939 hasConcept C2781110370 @default.
• W2768813939 hasConcept C502942594 @default.
• W2768813939 hasConcept C552990157 @default.
• W2768813939 hasConcept C553184892 @default.
• W2768813939 hasConcept C55493867 @default.
• W2768813939 hasConcept C71924100 @default.
• W2768813939 hasConcept C72591435 @default.
• W2768813939 hasConcept C86803240 @default.
• W2768813939 hasConcept C94915269 @default.
• W2768813939 hasConceptScore W2768813939C109316439 @default.
• W2768813939 hasConceptScore W2768813939C120665830 @default.
• W2768813939 hasConceptScore W2768813939C121332964 @default.
• W2768813939 hasConceptScore W2768813939C202751555 @default.
• W2768813939 hasConceptScore W2768813939C203014093 @default.
• W2768813939 hasConceptScore W2768813939C2781110370 @default.
• W2768813939 hasConceptScore W2768813939C502942594 @default.
• W2768813939 hasConceptScore W2768813939C552990157 @default.
• W2768813939 hasConceptScore W2768813939C553184892 @default.
• W2768813939 hasConceptScore W2768813939C55493867 @default.
• W2768813939 hasConceptScore W2768813939C71924100 @default.
• W2768813939 hasConceptScore W2768813939C72591435 @default.
• W2768813939 hasConceptScore W2768813939C86803240 @default.
• W2768813939 hasConceptScore W2768813939C94915269 @default.
• W2768813939 hasIssue "3" @default.
• W2768813939 hasLocation W27688139391 @default.
• W2768813939 hasLocation W27688139392 @default.
• W2768813939 hasLocation W27688139393 @default.
• W2768813939 hasLocation W27688139394 @default.
• W2768813939 hasOpenAccess W2768813939 @default.
• W2768813939 hasPrimaryLocation W27688139391 @default.
• W2768813939 hasRelatedWork W106037819 @default.
• W2768813939 hasRelatedWork W1965351869 @default.

• next